干扰素α联合拉米夫定治疗慢性乙型肝炎疗效观察

Observation of Curative Effect of Interferon-α in Combination with Lamivudine for Chronic Hepatitis B

目的:观察干扰素α联合拉米夫定治疗慢性乙型肝炎的疗效。方法:72例慢性乙型肝炎患者随机分为治疗组与对照组。治疗组35例,同时使用干扰素α及拉米夫定26wk后,再单独使用拉米夫定26wk;对照组37例,单独使用拉米夫定52wk。结果:治疗组与对照组HBeAg转阴率分别为42.86%、27.03%(P>0.05),HBVDNA转阴率分别为94.29%、62.16%(P<0.05)。结论:干扰素α联合拉米夫定治疗慢性乙型肝炎效果略优于单独使用拉米夫定。

OBJECTIVE：To evaluate the efficacy of interferon-α in combination with lamivudine for chronic hepatitis B. METHODS： A total of 72 patients with hepatitis B were randomized into 2 groups： 35（treatment group） were assigned to receive interferon-α plus lamivudine for 26 weeks before receiving lamivudine alone for another 26 weeks, and 37（control group） to receive lamivedine alone for 52 weeks. RESULTS： Proportions of HbeAg seroconversion in treatment group and control group were 42.86% and 27,03% , respectively（P 〉0.05） and proportions of HBV DNA seroconversion were 94.29% and 62.16%, respectively（P 〈 0.05）. CONCLUSION：The curative effect of interferon-a in combination with that of lamivudine is better than lamivudine alone for chronic hepatitis B.